A
Ascidian Therapeutics
Enables precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time
About Ascidian Therapeutics
Ascidian Therapeutics, operating under the website ascidian-tx.com, is a biotech startup that specializes in RNA exon editing. The company's name is inspired by sea squirts, or ascidians, which are known for their ability to re-engineer their transcriptome - the set of all RNA molecules in one cell or a population of cells. Ascidian Therapeutics aims to replicate this process in humans, with the goal of treating various diseases.
The company operates in the biotechnology market, specifically in the field of gene therapy. Its target clients are primarily healthcare providers and research institutions that are looking for innovative treatments for diseases. The company's business model revolves around developing and commercializing its RNA exon editing technology.
RNA exon editing is a process that allows for the precise alteration of genes after they have been transcribed from DNA into RNA. This technology provides the durability of gene therapy without the risks associated with direct DNA editing or gene replacement. It also maintains the natural patterns and levels of gene expression. By doing so, Ascidian Therapeutics can create full-length, functional proteins, which are crucial for the proper functioning of the human body.
The company generates revenue by licensing its technology to healthcare providers and research institutions. It may also earn income from the development and sale of therapies based on its technology.
In summary, Ascidian Therapeutics is a promising biotech startup that is leveraging the power of RNA exon editing to revolutionize the treatment of human diseases.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Boston, United States
- Employees
- 48
- Open positions
- 3
- Dealroom signal
- 69.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Genetics and genomics, Eye Diseases, RNA, Spinout, Genome Engineering, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Nov 2023 | $40M | $250M | Apple Tree Partners | ↗ |
| SERIES AOther financing | Oct 2022 | $50M | $200M | Apple Tree Partners | ↗ |
Growth signals
Latest recorded traffic for Ascidian Therapeutics is 4.6K monthly website visits, up 142.1% over the last three months. Ascidian Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Apple Tree Partners
Other known investors1 additional known investor
University of Pennsylvania
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ascidian Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ascidian Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.